{
    "clinical_study": {
        "@rank": "87514", 
        "arm_group": [
            {
                "arm_group_label": "bupropion hydrobromide", 
                "arm_group_type": "Experimental", 
                "description": "study drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety"
        }, 
        "brief_title": "Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  The primary efficacy endpoint is the mean change from Baseline to EOT in total CDRS-R\n           (raw) score.\n\n        -  The secondary efficacy endpoints include:\n\n             -  Proportion of subjects characterized as responders at EOT (\u226540% improvement from\n                Baseline total CDRS-R raw score)\n\n             -  Proportion of subjects characterized as in remission at EOT (total CDRS-R raw\n                score <29)\n\n             -  Mean change from Baseline to EOT in CGI-C.\n\n      Safety endpoints include:\n\n        -  Incidence of AEs\n\n        -  Change from Baseline to EOT in vital signs (blood pressure and radial pulse rate),\n           blood and urine laboratory panel, and ECG\n\n        -  Treatment discontinuation due to AEs\n\n        -  Suicidality as assessed by the C-SSRS score\n\n        -  Change from Baseline to EOT in sleep as assessed by the sleep subscale of the CDRS-R."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Male or female outpatients aged \u22657 to <18 years (at Screening Visit 1). 2. Provide\n             assent (subject) and written informed consent (parent/legal representative) and\n             Health Insurance Portability and Accountability Act (HIPAA) for study participation\n             (at Screening Visit 1).\n\n             3. Meet diagnostic criteria for MDD as defined in the DSM IV-TR5 at Screening Visits\n             1 and 1a (K-SADS-PL; see Appendix 17.2).\n\n             4. Current depressive episode of at least 4 weeks' duration as noted in the subject's\n             history (Screening Visit 1).\n\n             5. Total CDRS-R raw score \u226545 at both the Screening and Baseline Visits (Visits 1 and\n             2) (see Appendix 17.3).\n\n             6. CGI-S score of \u22654 at the Baseline Visit (Visit 2) (see Appendix 17.4).\n\n        Exclusion Criteria:\n\n          -  are unable to swallow medications without difficulty\n\n             \u2022  have known hypersensitivity to bupropion hydrobromide\n\n          -  are pregnant or planning to get pregnant or are lactating\n\n          -  Women of childbearing age unable to use at least one method of effective\n             contraception for the duration of the study\n\n          -  Previous history of attempted suicide are unable to understand and communicate\n             effectively with parent, Investigator, and study coordinator\n\n               -  are at immediate risk of requiring hospitalization, in the Investigator's\n                  opinion\n\n               -  have current seizure disorder or history of seizures or head trauma\n\n               -  have history or presence of clinically significant medical conditions or\n                  clinically important laboratory abnormalities\n\n               -  have ECG or physical examination abnormality at screening\n\n               -  have body weight less than the 3rd percentile or greater than the 97th\n                  percentile for age."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129751", 
            "org_study_id": "V01-BUPA-401"
        }, 
        "intervention": [
            {
                "arm_group_label": "bupropion hydrobromide", 
                "description": "study drug", 
                "intervention_name": "bupropion hydrobromide", 
                "intervention_type": "Drug", 
                "other_name": "Aplenzin"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupropion"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "able to swallow medications without difficulty", 
            "bupropion hydrobromide"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bridgewater", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08807"
                }
            }, 
            "investigator": {
                "last_name": "not available not available, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder", 
        "overall_contact": {
            "email": "denise.raimondo@valeant.com", 
            "last_name": "Denise Raimondo", 
            "phone": "908 927-1885"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary efficacy endpoint is the mean change from Baseline to EOT in total CDRS-R (raw) score.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129751"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Valeant Pharmaceuticals International, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Valeant Pharmaceuticals International, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}